Table 1.
General Characteristics of Post-Sustained Virologic Response Hepatocellular Carcinoma Cases and Non-Hepatocellular Carcinoma Controls
| Variable | Case (n=24) | Control (n=96) | p-value |
|---|---|---|---|
| Age, yr | 58.5 (53.3–60.0) | 59.0 (56.0–63.0) | 0.385 |
| Sex | |||
| Male | 13 (54.2) | 52 (54.2) | NA |
| Female | 11 (45.8) | 44 (45.8) | NA |
| Han nationality | 24 (100.0) | 96 (100.0) | NA |
| HBsAg positive | 0 | 0 | NA |
| Anti-HIV antibody | 0 | 0 | NA |
| HCV genotype, 1b/2a/UD* | 20/2/2 | 85/5/6 | NA |
| HCV RNA positive | 0 | 0 | NA |
| HCV-diagnosed months† | 108.0 (53.0–138.0) | 84.0 (56.0–144.0) | 0.748 |
| Post-SVR months‡ | 17.5 (11.0–39.0) | 50.0 (33.0–62.8) | <0.001 |
| Tumor size, cm | 1.5 (1.5–2.0) | - | - |
Data are presented as median (range) or number (%).
NA, not applicable; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; HCV, hepatitis C virus; UD, undermined; SVR, sustained virologic response.
*
Denotes the HCV genotype when diagnosed with chronic HCV infection;
†
Denotes the follow-up period after the diagnosis of an HCV infection;
‡
Denotes the duration between the SVR and the occurrence of hepatocellular carcinoma in the case group and the post-SVR period for the control group.